Recombinant human TNFRSF9 protein (Myc Tag, His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

Myc Tag, His Tag

Activity

not tested

Cat no : Eg0016

---

Validation Data Gallery

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <1.0 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human TNFRSF9 protein Leu24-Gln186 (Accession# Q07011) with a Myc tag and a His tag at the C-terminus.
• GeneID: 3604
• Accession: Q07011
• PredictedSize: 22.9 kDa
• Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD137, also known as TNFRSF9 or 4-1BB, is an inducible T cell surface receptor which belongs to the tumor necrosis factor receptor superfamily. CD137 is a transmembrane protein expressed on the surface of activated T-cells. In addition, activation-dependent expression of CD137 has also been found in B lymphocytes, monocytes, and diverse nonlymphoid cell types. CD137 provides a co-stimulatory signal that enhances the survival, and differentiation of cells, and has a crucial role in the development of CD8 cytotoxic T cells and anti-tumor immunity. Soluble forms of CD137 (sCD137) are generated by differential splicing and are released by activated lymphocytes. Elevated serum sCD137 level has been associated with some diseases, including rheumatoid arthritis, multiple sclerosis, chronic lymphocytic leukemia, and acute coronary syndrome.

References:

1.Vinay, D S et al. Seminars in immunology vol. 10,6 (1998): 481-9.
2.Schwarz, H et al. Blood vol. 85,4 (1995): 1043-52.
3.Nakaima, Yukana et al. PloS one vol. 8,5 (2013): e64425.
4.Michel, J et al. European journal of immunology vol. 28,1 (1998): 290-5.
5.Sharief, M K et al. European journal of neurology vol. 9,1 (2002): 49-54.
6.Furtner, M et al. Leukemia vol. 19,5 (2005): 883-5.
7.Yan, Jinchuan et al. Clinics (Sao Paulo, Brazil) vol. 68,2 (2013): 193-8.